The verdict is out for now. Tilray's second quarter sales surged 95.2% from the prior year to $9.7 million, beating Wall Street estimates of $9 million. But, the company's loss per share came in at 17 cents, worse than estimates for a loss of 9 cents a share.
The net loss included non-cash compensation charges of $5.6 million. Tilray didn't issue an adjusted per share figure.
TheStreet looks at Tilray from a bull vs. bear perspective.
Check out more cannabis coverage from TheStreet here.
Interested in cannabis investing? You won't want to miss the 'Green Market Summit on the Economics of Cannabis' on Sept. 14. Quickly register here.